Related references
Note: Only part of the references are listed.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: Pregnancy and Pediatrics
Uma Mahadevan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
Eugene O. Major
ANNUAL REVIEW OF MEDICINE (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Influence of Anti-Tumor Necrosis Factor Therapy on Cancer Incidence in Patients With Rheumatoid Arthritis Who Have Had a Prior Malignancy: Results From the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS CARE & RESEARCH (2010)
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up
C. W. Lees et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
G. R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Pneumocystis jiroveci Pneumonia in Patients With Rheumatoid Arthritis Treated With Infliximab: A Retrospective Review and Case-Control Study of 21 Patients
Yukiko Komano et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
Crohn's Disease, Hepatosplenic T-cell Lymphoma and No Biological Therapy: Are We Barking Up the Wrong Tree?
Gordon Moran et al.
INFLAMMATORY BOWEL DISEASES (2009)
Adalimumab Safety in Global Clinical Trials of Patients with Crohn's Disease
Jean-Frederic Colombel et al.
INFLAMMATORY BOWEL DISEASES (2009)
Incidence and Clinical Significance of Immunogenicity to Infliximab in Crohn's Disease: A Critical Systematic Review
Andrea Cassinotti et al.
INFLAMMATORY BOWEL DISEASES (2009)
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
J. F. Rahier et al.
JOURNAL OF CROHNS & COLITIS (2009)
Hepatosplenic T Cell Lymphoma Associated with Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease: Update
Ann Corken Mackey et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2009)
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
Laurent Beaugerie et al.
LANCET (2009)
Monoclonal anti body-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
Kenneth R. Carson et al.
LANCET ONCOLOGY (2009)
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
Yiping Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
Hans Linda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease
Frank Hoentjen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis
Soko Setoguchi et al.
AMERICAN HEART JOURNAL (2008)
Does tumor necrosis factor a inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Joachim Listing et al.
ARTHRITIS AND RHEUMATISM (2008)
Infliximab for Inflammatory Bowel Disease in Denmark 1999-2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality
Sarah Caspersen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
Natalizumab and PML: a risky business?
David B. Clifford
GUT (2008)
Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease
Ferenc Izbeki et al.
INFLAMMATORY BOWEL DISEASES (2008)
Listeria infections associated with infliximab:: case reports
Thomas Kesteman et al.
CLINICAL RHEUMATOLOGY (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?
Joel R. Rosh et al.
INFLAMMATORY BOWEL DISEASES (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy:: A review of 84 cases
Nirmal Kaur et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation
Frederick Wolfe et al.
ARTHRITIS AND RHEUMATISM (2007)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease
Stephen I. Rennard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Immortal time bias in observational studies of drug effects
Samy Suissa
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
Ann Corken Mackey et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2007)
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
M. H. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
GR Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities - A large, randomized, placebo-controlled trial
R Westhovens et al.
ARTHRITIS AND RHEUMATISM (2006)
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
E Baecklund et al.
ARTHRITIS AND RHEUMATISM (2006)
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia - Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy
F Wolfe et al.
ARTHRITIS AND RHEUMATISM (2006)
Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study
L Biancone et al.
GUT (2006)
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to Fludarabine and Alemtuzumab
S Mittal et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Infections in patients with rheumatoid arthritis treated with biologic agents
J Listing et al.
ARTHRITIS AND RHEUMATISM (2005)
Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis
J Torre-Cisneros et al.
RHEUMATOLOGY (2005)
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
A Kandiel et al.
GUT (2005)
Natalizumab and progressive multifocal leukoencephalopathy
B Adelman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
J Askling et al.
ARTHRITIS AND RHEUMATISM (2005)
TNF-blocking agents and tuberculosis: new drugs illuminate an old topic
J Keane
RHEUMATOLOGY (2005)
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
M De Bandt et al.
ARTHRITIS RESEARCH & THERAPY (2005)
High Incidence of Anergy in Inflammatory Bowel Disease Patients Limits the Usefulness of PPD Screening Before Infliximab Therapy
William S. Mow et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
F Wolfe et al.
ARTHRITIS AND RHEUMATISM (2004)
Cavitating pneumonia after treatment with infliximab and prednisone
SM Arend et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists
L Bergstrom et al.
ARTHRITIS AND RHEUMATISM (2004)
Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis
G Haerter et al.
CLINICAL INFECTIOUS DISEASES (2004)
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
JF Colombel et al.
GASTROENTEROLOGY (2004)
Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone
SM Singh et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2004)
Granulomatous infectious diseases associated with tumor necrosis factor antagonists
RS Wallis et al.
CLINICAL INFECTIOUS DISEASES (2004)
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk -: A multicenter active-surveillance report
JJ Gómez-Reino et al.
ARTHRITIS AND RHEUMATISM (2003)
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease:: A prospective cohort study
S Vermeire et al.
GASTROENTEROLOGY (2003)
Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: A possible healthcare-associated case?
FG De Rosa et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2003)
Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy
KL Wood et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
RJ Farrell et al.
GASTROENTEROLOGY (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate
JM van der Klooster et al.
INTENSIVE CARE MEDICINE (2003)
Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy
D Helbling et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2002)
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
JH Lee et al.
ARTHRITIS AND RHEUMATISM (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Inflammatory bowel disease is not associated with an increased risk of lymphoma
JD Lewis et al.
GASTROENTEROLOGY (2001)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Hodgkin's disease risk is increased in patients with ulcerative colitis
D Palli et al.
GASTROENTEROLOGY (2000)
Share Paper
